![](/img/cover-not-exists.png)
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Aghajanian, Carol, Bell-McGuinn, Katherine M., Burris, Howard A., Siu, Lillian L., Stayner, Lee-Ann, Wheler, Jennifer J., Hong, David S., Kurkjian, Carla, Pant, Shubham, Santiago-Walker, Ademi, GauvinLanguage:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-018-0591-z
Date:
April, 2018
File:
PDF, 583 KB
english, 2018